汉森制药公司简介(外盘期货在线喊单数据提前布局)
汉森制药公司简介(外盘期货在线喊单数据提前布局)
本文目录一览：
1、汉森制药公司简介
1.1 项目名称：
中药材种植及加工示范基地项目。
1.2 项目单位：
湖南汉森制药股份有限公司。
1.3 拟建地点：
湖南省益阳市东部新区。
1.4 产品方案与生产规模
中药材种植及加工示范基地建设总体工程用地2300亩。汉森制药 中药材种植及加工示范基地项目计划占地1850亩，建设用地450亩， 主要用于中药材收购、加工、储存、检测及展示销售。项目用地涵盖 了沧水铺镇的砂子岭村、黄团岭村、泉交河镇的龙泉村3个村，共36 个组。后续用地、储备用地在1200亩左右，涉及现有3个村的11个组， 各项条件与上相同。
各种适合种植的中药材在基地种植的分布情况图
（1）中药材种植基地建设：种植基地工程总规模1850亩。从适 合中药材种植基地的中药材品种中选取以下11种中药材进行种植：木 香、枳壳、白芷、白术、山药、白芍、蒲公英、鱼腥草、益母草、地 黄、桔梗等。
（2）中药材饮片加工厂及商业配套：加工厂工程建设配套用地 450亩。其中包括整体收购林芳生态园。
1.4 建设年限
项目建设期需 3 年。
1.5 总投资
投资总额：8000 万元。其中： 固定资产投资：7100 万元，占投资总额的 88.75 % ，流动资金投入：780 万元，占投资总额的 9.75 %，不可预计资金：120 万元，占投资总额的 1.50 %。
1.8 经济效益指标
（1）中医药科研展示体验中心经济效益
中药材种植及加工示范基地 2300 多亩土地，其中中药材饮片加工厂及商业配套建设用地 450 亩，建设项目有商业经济区、名贵中药材及花卉植物种植观赏区、中药养生保健区、中药科研展示区、药用植物育种区等。同时中药材种植及加工示范基地优越的地理位置、便捷的交通网络、优美的自然环境完全可以开发旅游地产，这些项目建成后，将产生很高的经济效益。
（2）土地效益
土地效益除产生生产效益外，土地升值空间也较大。一是土地流转价格的升值，目前土地流转价格呈不断上升态势。赫山区部分地方林地已达 400 元/亩每年，水田 800 元/亩每年，并且根据目前国家土地政策，农村土地、集体土地可同价入市，土地升值还有更进一步的空间。
（3）林芳资产增值
林芳整体收购价为 3680 万元（含宾馆），林芳生态园为国家 2A级景点、国家水土保持科技示范园、省五星级休闲农庄、省五星级农业旅游景点，是一家经营 7 年的市、区重点旅游企业。林芳生态园区4内各类花卉、苗木的资产评估价值达 6800 多万元，具备较大的资产增值空间。
（4）林业效益
林业效益除了林芳生态园各类花卉苗木增值外，公司回购的 1200多亩林地树木，既保持了水土，又可美化项目环境，更主要的是土地一旦流转成功，一年后，它将产生巨大的有形效益和无形效益。有形效益是树木的自然增长，项目建成后的升值，更主要的是让项目环境美化提前了至少 10 年（即无形效益）。
1.9 项目提出的背景
我国的中药材主要来源于天然野生自然资源，很多宝贵的药种由于人口不断增长、生态受到破坏，加之多年来不断的采挖，使野生中药材不断减少，资源遭受了严重的破坏，储量也急剧减少，有的种类濒临灭绝，市场中药材的供应已远远不能满足人类的需要。其主要原
因有：
（1）中药材需求量不断增长造成野生中药材资源遭到严重破坏。
随着人口不断增长，国际社会对中药材治疗的认识不断提高，中药材需求量不断增长，一些常用大宗中药材出现供不应求，引发中药材过度采挖，从而造成中药材资源遭受严重破坏。
（2）中药材生存环境的破坏造成野生中药材资源的短缺。
由于人们对山林、水土的保护不力，致使中药材的生存环境遭到严重破坏，加上春旱少雨等自然灾害的影响，亦对中药资源产生了破坏性的作用。
（3）中药材的短缺和价格的上涨造成野生中药材资源的掠夺性采挖。
随着市场价格的进一步放开，受农副产品比价的影响，药材收购价格逐年上涨，争先抬价抢购现象屡见不鲜，进一步刺激了农民采药的积极性，不顾资源现状，杀鸡取卵，掠夺性采挖。
（4）中药材生长环境、采收和加工的乱象也造成野生中药材资源的质量严重下降。
中药材是防病治病的特殊商品，其质量的优劣与药材本身所含的化学成份密切相关，而化学成份的多少、有无又与药材的采收期和加工方法紧密相关，如黄芩、苍术、柴胡、赤芍、刺五加、黄精等根及根茎类药材以初春秋末采收，有效成分含量高，质量好，而实际情况却是春、夏、秋三季连续采刨，又不按传统方法加工，致使中药材商品质量严重下降。
鉴于上述原因，必须采取相应措施，对野生中药材资源加强保护，合理的开发利用。同时对需求量大的常用大宗药材，变野生为种植，为中药材产业的发展提供优质丰富的中药材。
2.0 项目提出的依据
近年来，由于全球气候发生变化导致的生态环境的巨大改变，以及人们对中药资源不合理的开发和采收等因素，造成了许多中药材资源的枯竭和种质资源退化严重，使得中药材资源的质量很难得到保证，已引起了各方面人士的高度重视。为了保证提供高质量的中药材原料，确保中药材的疗效，在道地药材研究的基础上选择品种并在最适宜生长地域按照现代规范技术进行种植，建设现代规范化种植基地是中药材现代化的前提和保证。
（1）中药材的现代化种植是现代中药材生产的重要保证。
中药材的种植不同于一般的农作物和经济作物的种植。中药材种植的质量关系到人们的健康和生命安全，它要求的技术含量高，必须根据每一种药材的生长特性进行种植和管理，对环境、气候因子、采收、施肥的要求严格，如同样是桑寄生：寄生于桑、柿、槐、荔枝、沙梨等植物上的干燥带叶茎枝，含槲皮素、醍蓄甙等成分，具有补肝肾、去风湿、强筋骨、养血、安胎、降压的功效；而寄生于马桑上的带茎枝叶因含有马桑内酯等毒素，不可做中药材。只有根据特定的环境要求进行严格的种植和管理，才能保证中药材的质量。因而，中药材的种植必须有专业的人才和专家参与管理和经营。专业的人才和专家不可能依托个体、分散的经营与种植，只有一定的组织和企业，才能发挥专家的指导作用，企业的参与有利于促进中药材植业的发展。
（2）中药材的集约化种植是中药材规范化、现代化的基础。
分散的、零星的、各自为政的个体种植方式早已不适应于现代中药材的发展。长期以来，我国中药材的生产是以原始、粗放、分散的方式进行，大多都是凭经验进行种植和管理，种植者与种植者之间差异很大，缺乏统一规范的种植和管理，批与批之间质量相差很远。中药材要发展，要打破现有的状况和格局，首先质量是关键，稳定和高等的质量来源于严格规范的种植管理和技术，科学规范化和集约化的种植和管理；其次市场是保证，中药材种植规划必须建立在市场调查的基础之上，只有在广泛的市场调查中才能科学地规划种植面积。只有企业的参与才有可能对中药材种植进行全面科学的规划与管理，并对市场进行全面的分析与论证，严格规范管理，保证质量和产量。
（3）科学技术是中药材现代规范化种植的动力
中药材的种类繁多、生物活性多样。中药材是中药的原料和治病的物质基础，是一种特殊的商品，“有效性、安全性、稳定性和质量的可控性”是其质量的基本保证，也是现代中药材的重要指标。为了确保中药材的稳定性、安全性和有效性，必须加强中药材种植的科研力度，对中药材种植过程中的每一生产环节进行全面的、深入的、细致的研究。优良的栽培技术是中药材品质的重要保障。个体的、分散式的种植方式不能也不可能对中药材种植进行深入的研究，只有集约式的规范管理种植才有可能对中药材种植的每一个环节、每一个因子进行深入的科学研究，从而促进中药材种植业的发展。
（4）中药材资源可持续发展是中药材现代化种植的前提
优质中药材是在一定的生态地理环境下形成的质优效佳产品。自然条件或栽培条件发生改变，植物生长发育及其药材形态结构也随之发生改变，种质资源的退化是种植中药材不可避免的。优良的栽培技术是*限度防止中药材品种的退化，并培育出优良的中药材种植品种，保持中药材的可持续发展的保障。每一种中药材均有其最小的种群面积数，小于该面积要保存其优良的特性和稳定的更新几乎是不可能的，分散的、小面积的种植不利于中药材品质的保存和持续发展，只有一定的种群种植面积，才有可能保持稳定的特性，营造其适合自身发展*生存环境，并选育出优良的品种。集约化的中药材规模种植有利于自身优良品种的选育及中药材的可持续发展，并营造出其适宜的生存环境。
因此，发挥企业在现代中药材种植业的主导作用，以集约化、科学化、现代化的管理，建立*中药材，对保证中药材的质量和疗效，更好地创促进我国中药材的发展，提高我国中药材在国际上的竞争力有着非常重要的意义。
目 录
第一章 总论································································································1
1.1 项目名称································································································1
1.2 项目单位································································································1
1.3 拟建地点································································································1
1.4 产品方案与生产规模············································································1
1.5 建设年限································································································2
1.6 总投资···································································································2
1.7 资金解决途径··························································································2
1.8 经济效益指标··························································································2
1.9 综合结论································································································4
1.9.1 项目总体评价························································································4
1.9.2 可行性研究结论·····················································································5
1.9.3 问题与建议···························································································5
第二章 项目建设的背景和必要性·······························································6
2.1 项目提出的背景和依据··············································································6
2.1.1 项目提出的背景·····················································································7
2.1.2 项目提出的依据·····················································································8
2.2 项目建设的必要性和经济意义····································································10
2.2.1 项目建设的必要性·················································································10
2.2.2 项目建设的意义····················································································13
第三章 项目建设的条件·················································································15
3.1 区位优势条件·························································································15
3.2 交通优势·······························································································15
3.2.1 公路···································································································15
3.2.2 铁路···································································································15
3.2.3 港口机场·····························································································15
3.3 自然条件·······························································································16
3.3.1 地理条件·····························································································16
3.3.2 气候条件·····························································································16
3.4 原材料条件····························································································16
第四章 项目建设的市场分析与预测························································18
4.1 中药材种植产品简介················································································18
4.1.1 木香···································································································18
4.1.2 枳壳···································································································18
4.1.3 白芷···································································································19
4.1.4 白术···································································································19
4.1.5 山药···································································································20
4.1.6 白芍···································································································21
4.1.7 蒲公英································································································21
4.1.8 鱼腥草································································································22
4.1.9 益母草································································································22
4.1.10
地黄··································································································22
4.1.11
桔梗··································································································23
4.2 市场需求································································································23
4.2.1 国内市场需求·······················································································24
4.2.2 国际市场需求·······················································································26
4.3 社会需求································································································28
4.4 生态改善································································································28
4.5 经济发展································································································28
第五章 项目规模与建设方··············································································29
5.1 项目建设规模·························································································29
5.1.1 建设的指导思想与建设原则·····································································29
5.1.2 中药材种植基地建设总体规模··································································29
5.2 中药材种植基地建设方案··········································································30
5.2.1 中药材种植基地建设规模········································································30
5.2.2 中药材种植基地中药材品种规划·······························································30
5.2.3 中药材种植基地中药材产品产量规划·························································31
5.2.4 种植、栽培技术方案···············································································32
5.2.5 技术推广、示范和培训············································································60
5.2.6 技术保障服务体系建设············································································61
5.3 中药材饮片加工厂及商业配套建设规模························································61
5.3.1 中药材饮片加工厂建设内容·······································································61
5.3.2 中药材商业配套建设················································································68
5.4 公用工程································································································72
5.4.1 给、排水工程························································································725.
4.2 供电工程·····························································································72
第六章 组织机构与人力资源配置·····································································74
6.1 组织及工作制度······················································································74
6.1.1 组织与管理体系····················································································74
6.1.2 基地服务体系·······················································································74
6.2 项目管理机构·························································································74
6.3 劳动定员································································································75
6.4 人员培训································································································
75
6.5 劳动保护与安全卫生教育··········································································76
6.6 项目运行管理·························································································76
6.6.1 项目管理·····························································································76
6.6.2 资金管理·····························································································
76
第七章 环境影响评价····················································································78
7.1 中药材种植基地对环境影响·······································································78
7.1.1 整地对水土流失的影响···········································································78
7.1.2 施用化肥、农药对环境影响······································································78
7.1.3 对野生动物栖息环境的影响·····································································78
7.1.4 中药材饮片加工厂对环境影响··································································78
7.1.5 中药材保健疗养馆对环境影响··································································78
7.2 环境保护措施及评价················································································79
7.2.1 整地技术措施·······················································································79
7.2.2 施肥（药）技术措施···············································································79
7.2.3 编制依据及原则····················································································79
7.2.4 环境保护措施·······················································································80
第八章 项目实施进度····················································································82
8.1 建设工期·································································································82
8.2 项目实施进度安排···················································································82
第九章 投资估算与资金筹措···········································································83
9.1 投资估算依据·························································································83
9.2 土地与厂房投资······················································································83
9.2.1 中药材种植基地土地流转成本··································································83
9.2.2 中药材饮片加工厂建筑面积·····································································85
9.2.3 中医药科研展示体验中心建筑投资····························································85
9.3 办公设备·································································································85
9.4 生产设备·································································································85
9.5 配套·····································································································85
9.6 管理费用································································································85
9.7 能源动力································································································86
9.8 铺底流动资金·························································································86
9.9 固定资产投资·························································································86
9.10 流动资金投入·························································································86
9.11 总投资·································································································86
9.12 资金解决途径··························································································87
第十章 效益分析与评价·················································································88
10.1 计算指标与费率标准···············································································88
10.2 成本分析······························································································90
10.2.1 折旧与分摊·························································································90
10.2.2 总成本费用·························································································91
10.3 销售收入预测························································································91
10.4 销售税金······························································································92
10.5 利润及分配···························································································92
10.6 财务指标估算························································································92
10.6.1 财务内部收益率···················································································92
10.6.2 投资回收期·························································································93
10.6.3 投资利润率（税后）··············································································93
10.6.4 投资利税率·························································································93
10.6.5 不确定分析·························································································93
10.7 效益分析······························································································94
10.7.1 直接经济效益评价················································································94
10.7.2 潜在经济效益评价················································································94
10.7.3 社会效益····························································································95
10.7.4 无形资产效益······················································································96
第十一章 风险分析·······················································································97
11.1 项目风险分析························································································97
11.2 技术与经营风险·····················································································97
11.3 市场风险······························································································97
11.4 规避分析的主要措施···············································································98
第十二章 可行性研究结论与建议·····································································99
12.1 项目总体评价·························································································99
12.2 可行性研究结论······················································································99
11.3 问题与建议···························································································100
外盘期货简介：
期货合约，就是指由期货交易所统一制定的、规定在将来某一特定的时间和地点交割一定数量标的物的标准化合约。因此期货交易中只存在标准手，即单次成交的合约数至少为1手或是整数倍，不存在更小份额或切割式的合约成交形式。
外盘期货是指交易所建立在中国大陆以外的期货交易。以美国四大期货交易所(CME芝加哥商品交易所，CBOT芝加哥期货交易所，NYMEX纽约商业交易所，COMEX纽约商品交易所)、英国(LME伦敦金属交易所)等交易所的产品是国际上最常见、交易最活跃的期货合约，并引领着国际期货市场的发展。
有些美国期货合约品种如大豆、铜对国内期货价格变动会有影响，因此国内投资者可以参考外盘行情。同时，大型生产商与贸易商也可根据外盘行情做好套期保值，对冲现货交易损失。
——外盘期货主要分为两大类：
一、金融期货：
1、指数类期货，包括美元指数，A50，恒生指数，日经指数，标普，道琼斯指数，德国指数等;
2、外汇类期货，包括欧元，英镑，日元，澳元，加元，港币等;
3、国债类期货，包括美国5年期，10年期，30年期的国债等。
二、商品期货：
1、金属类期货：铜，铝，铅，锌，锡，镍，黄金，白银等贵金属期货;
2、农产品类期货：大豆，玉米，小麦，可可，咖啡，棉花等;
3、能源类期货：原油，天然气等。
外盘投资优势：
①全球化交易平台港交所 芝加哥商品交易所 欧洲期货交易所 等全球期货市场
②市场规范透明市场制度完善 证监会监管 充分保障投资者合法权益③T+0交易随买随卖可买涨买跌 当天买卖 锁定收益 规避风险
④交易品种多样恒生指数 美原油 美黄金 德国指数等全球热门交易品种
⑤交易时间更长全天近23小时交易时间 无涨跌停板限制
⑥高杠杆以小博大保证金制度 以小博大 实现收益*化
参与国际期货有两种方式：
(一)、直接去香港期货公司开设账户。
a.有效的身份证和护照或港澳通行证副本
b.若现居住地址与身份证地址不同，需提供有效的地址证明，如三个月内的公共事业缴费单(水费单，电费单，燃气单，电话费单等..)或房产证副本
c.香港银行卡(出入金)
去香港期货公司办理外盘期货开户的条件及流程不仅复杂门槛也较高，不仅需要本人亲自去香港开户，而且开户门槛至少要十万以上的人民币资金才能开户，同时国家法律规定中国公民每人每年最多限额兑换5万美金或者等值外币，所以外盘期货开户又存在换汇难的问题。
(二)、在大陆通过香港期货公司授权的大陆代理开户
国内投资者可以在代理商获取开户链接，实现网上自助开户，10分钟即可拥有属于自己的投资账户，省去烦琐的开户流程，目前全国的开户模式都是这样。
公司给客户后台统一垫资，客户*可用300美金操作1手美原油，出入金安全快捷，客户做的**通过我们的主账户期货公司的跑道进入全球交易市场。
期牛策略目前在外盘期货开户交易领域积累了广泛的行业经验。坚持”专业服务、客户至上”的宗旨，致力于为国内投资者打造高效快捷的外盘期货开户服务
本公司作为博弈大师信管家的合作单位，信管家拥有最为专业的软件工程师，搭建了覆盖中国境内,新加坡，日韩，香港及美国的专线网络，推广全球化交易平台，结算系统，风险管理平台及程序化交易等产品，为公司客户提供稳定，快捷的交易系统，为客户交易保障护航。
信管家软件：所属上海彭博财经旗下，是国内*权威的外盘期货交易软件 稳定，不卡顿，不划点，0延迟 自动止损止盈 简单易操作 支持手机交易。
优质平台:
一个好平台是成功道路上的一把利剑，一个全新的专门服务于客户的平台诞生了，为您的投资带来*便利。黄金、白银、原油、天然气、恒指、*保证金一手300美金，手续费低。无点差，无隔夜费。美黄金波动0.1(10美金)美原油波动0.01(10美金)恒指波动1指数点(50港币)*持仓*单笔下单无任何限制、入金人民币自动换算美元、 一个*操作成本的平台才是真正适合原油，贵金属的交易平台
目前外盘期货由于交易量大、流动性好、政府监管严格受到投资者欢迎。但随着市场火爆出现了很多假盘、对du盘公司，有的模仿文华财经、信管家等软件。他们用相对较低的手续费诱惑投资者上当。让投资者无法识别真假上当受骗。
小编来告诉大家怎么识别真假盘、做投资选择正规渠道、保障资金安全不要贪便宜。
第一步.：拿到账户后，做如下工作：选择一个在特定时间段基本不波动的合约。
在行情不是很急的阶段，选择离当前行情比较远的价位上反复用固定的手数挂单、撤单，由于这些品种的价格和挂单数量的波动频率非常低，真实的账户可以在任意行情软件里面看到由于挂单和撤单造成的挂单总数增减，因为模拟账户的交易是虚假的，是不可能在行情软件上显示出来的，故而，软件真实性瞬间确定! (以上方法能让您有效防范风险，真实、合法的进行期货投资。)
第二步：正规的期货公司 都能提供客户交易之后的交割单予以核对。
证券代码：002412 证券简称：汉森制药 公告编号：2021-048
本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。
重要内容提示:
1.董事会、监事会及董事、监事、*管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。
2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完整。
3.第三季度报告是否经过审计
□ 是 √ 否
一、主要财务数据
(一)主要会计数据和财务指标
公司是否需追溯调整或重述以前年度会计数据
□ 是 √ 否
(二)非经常性损益项目和金额
√ 适用 □ 不适用
单位：元
其他符合非经常性损益定义的损益项目的具体情况：
□ 适用 √ 不适用
公司不存在其他符合非经常性损益定义的损益项目的具体情况。
将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益项目的情况说明
□ 适用 √ 不适用
公司不存在将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目的情形。
(三)主要会计数据和财务指标发生变动的情况及原因
√ 适用 □ 不适用
1.应收票据期末余额较年初减少43,280,078.87元，下降62.05%，主要系母公司为筹措资金将34,591,847.57元银行承兑汇票贴现所致。
2.其他应收款期末余额较年初增加15,736,600.15元，增长44.77%，主要系子公司汉森健康产业（湖南）有限公司缴纳土地保证金2,580万元所致。
3.应收利息期末余额较年初减少493,434.00元，下降***，主要系收回长沙三银房地产开发有限公司借款利息所致。
4.其他流动资产期末余额较年初增加48,567,704.16元，增长199.97%，主要系子公司云南永孜堂制药有限公司购买银行理财产品所致。
5.在建工程期末余额较年初减少15,212,366.49元，下降56.93%，主要系在建工程转固所致。
6.其他非流动资产期末余额较年初增加65,199,833.79元，增长82.01%，主要系支付长沙三银房地产开发有限公司购房款所致。
7.合同负债期末余额较年初减少2,293,389.57元，下降65.11%，主要系年初预收客户款项本期发货所致。
8.其他应付款期末余额较年初增加47,225,681.02元，增长210.00%，主要系暂未支付的业务费用增加所致。
9.其他流动负债期末余额较年初减少298,270.63元，下降65.14%，主要系年初预收的客户款项对应的增值税本期发货所致。
10.其他综合收益期末余额较年初增加7,803,735.27元，增长90.21%，主要系按权益法核算的湖南三湘银行股份有限公司可转损益的其他综合收益增加所致。
11.本期税金及附加较上期增加3,667,591.41元，增长37.69%，主要系本期销售收入增加、其对应的增值税也增加、按增值税计提的城建税及教育费附加增加和本期上缴的水利建设基金增加所致。
12.本期销售费用较上期增加78,665,096.75元，增长31.82%，主要系本期销售收入及各项销售活动较上期增加所致。
13.本期其他收益较上期减少7,359,534.36元，下降78.74%，主要系本期收到的与日常活动相关的政府补贴减少所致。
14.本期投资收益较上期增加16,481,080.16元，增长43.40%，主要系按权益法核算的湖南三湘银行股份有限公司的投资收益增加所致。
15.本期信用减值损失较上期减少609,488.39元，下降58.44%，主要系本期计提的坏账准备增加所致。
16.本期资产减值损失较上期减少127,647.31元，下降47.72%，主要系本期计提的存货跌价准备增加所致。
17.本期营业外收入较上期减少223,071.09元，下降47.89%，主要系本期无与日常活动无关的政府补助所致。
18.本期营业外支出较上期减少520,632.67元，下降63.57%，主要系子公司云南永孜堂制药有限公司上期支付补税滞纳金所致。
19.本期净利润较上期增加28,739,524.37元，增长33.91%，主要系投资收益增加和主营业务收入增加所致。
20.本期其他综合收益的税后净额较上期增加7,951,595.52元，增长5377.78%，主要系本期按权益法核算的湖南三湘银行股份有限公司可转损益的其他综合收益增加所致。
21.本期综合收益总额较上期增加36,691,119.89元，增长43.37%，主要系归属于上市公司股东的净利润和其他综合收益的税后净额增加所致。
22.本期基本每股收益较上期增加0.0571元，增长33.91%，主要系归属于上市公司股东的净利润增加所致。
23.经营活动产生的现金流量净额较上期增加60,069,731.27元，增长50.56%，主要系本期销售商品、提供劳务收到的现金增加所致。
24.投资活动产生的现金流量净额较上期减少131,099,697.71元，下降666.15%，主要系本期母公司购买房屋产权支付的现金和子公司云南永孜堂制药有限公司购买理财产品支付的现金增加所致。
25.筹资活动产生的现金流量净额较上期增加88,327,970.94元，增长94.03%，主要系本期取得借款收到的现金增加、偿还债务支付的现金减少和上期进行了现金分红所致。
26.现金及现金等价物净增加额较上期增加17,298,004.50元，增长333.46%，主要系本期经营活动产生的现金流量净额较上期增加60,069,731.27元，投资活动产生的现金流量净额较上期减少131,099,697.71元，筹资活动产生的现金流量净额较上期增加88,327,970.94元所致。
二、股东信息
(一)普通股股东总数和表决权恢复的优先股股东数量及前十名股东持股情况表
单位：股
(二)公司优先股股东总数及前10名优先股股东持股情况表
□ 适用 √ 不适用
三、其他重要事项
√ 适用 □ 不适用
四、季度财务报表
(一)财务报表
1、合并资产负债表
编制单位：湖南汉森制药股份有限公司
2021年09月30日
单位：元
法定代表人：刘正清 主管会计工作负责人：戴江洪 会计机构负责人：郭志蓉
2、合并年初到报告期末利润表
单位：元
本期发生同一控制下企业合并的，被合并方在合并前实现的净利润为：0.00元，上期被合并方实现的净利润为：0.00元。
3、合并年初到报告期末现金流量表
单位：元
(二)财务报表调整情况说明
1、2021年起*执行新租赁准则调整*执行当年年初财务报表相关项目情况
√ 适用 □ 不适用
是否需要调整年初资产负债表科目
□ 是 √ 否
不需要调整年初资产负债表科目的原因说明
本次会计政策变更及公司适用新租赁准则是根据财政部相关文件的要求进行的合理变更，能更加客观、公允地反映公司财务状况和经营成果，符合《企业会计准则》的相关规定。本次会计政策变更不涉及对公司以前年度的追溯调整，不会对公司财务状况、经营成果和现金流量产生重大影响。
2、2021年起*执行新租赁准则追溯调整前期比较数据说明
□ 适用 √ 不适用
(三)审计报告
第三季度报告是否经过审计
□ 是 √ 否
公司第三季度报告未经审计。
湖南汉森制药股份有限公司董事会
2021年10月28日
证券代码：002412 证券简称：汉森制药 公告编号：2018-064
湖南汉森制药股份有限公司
关于使用自有闲置资金进行风险投资的进展公告
本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误导性陈述或者重大遗漏。
湖南汉森制药股份有限公司（以下简称“公司”“本公司”）于2018年9月28日召开2018年第一次临时股东大会，会议审议通过了《关于使用自有闲置资金进行风险投资的议案》，同意公司在确保公司日常运营和资金安全、有效控制风险的前提下，使用自有闲置资金不超过1亿元进行风险投资，投资范围包括股票及其衍生品投资、基金投资、期货投资、房地产投资及以上述投资为标的的证券投资产品。在上述额度范围内，资金可循环使用，同时授权公司董事长在额度范围内签署风险投资相关的协议、合同。
根据上述决议，公司现将近期进行风险投资相关事宜公告
一、风险投资的概述
1.2018年12月28日，公司与湖南同发投资有限公司（以下简称“同发投资”）、湖南省中欣房地产开发集团有限公司（以下简称“中欣房产”）、湖南安电工程技术服务合伙企业（以下简称“安电工程”）、湖南安鑫物流有限公司（以下简称“安鑫物流”）、长沙澄海实业有限公司（以下简称“澄海实业”）、湖南省八环建筑工程有限公司（以下简称“八环建筑”）作为新增投资方与标的企业长沙三银房地产开发有限公司（以下简称“三银地产”）及其原股东三一集团有限公司（以下简称“三一集团”）在湖南长沙签订了《关于长沙三银房地产开发有限公司之增资扩股协议》，公司使用自有资金以现金方式出资人民币6,320万元参股三银地产。本次增资扩股完成后，三银地产的注册资本将由人民币1,000万元增加到40,000万元，公司将持有三银地产15.80%的股权。
2.公司已于2018年9月11日召开的第四届董事会第八次会议、第四届监事会第六次会议及2018年9月28日召开2018年第一次临时股东大会，审议通过了《关于使用自有闲置资金进行风险投资的议案》，同意公司在确保公司日常运营和资金安全、有效控制风险的前提下，使用自有闲置资金不超过1亿元进行风险投资。此次参股三银地产出资金额为人民币6,320万元，在审批金额之内，无需再次提交董事会及股东大会审议。
3.此次对外投资不构成关联交易，不构成《上市公司重大资产重组管理办法》规定的重大资产重组。
4.公司不存在以下情况：使用闲置募集资金暂时补充流动资金期间；将募集资金投向变更为*性补充流动资金后十二个月内；将超募资金*性用于补充流动资金或归还银行贷款后的十二个月内。
二、风险投资主体情况
除公司作为此次增资扩股新增投资方的丙方1外，其他投资主体（包括原股东）基本情况
1.三一集团有限公司（原股东，乙方）
住所：长沙市经济技术开发区三一路三一工业城三一行政中心三楼
类型：有限责任公司(自然人投资或控股)
统一社会信用代码：91430000722592271H
法定代表人：唐修国
注册资本：32,288万人民币
经营范围：以自有合法资产进行高新技术产业、汽车制造业、文化教育业、新能源、互联网业的投资；机械设备及其零部件的研发、制造、销售、租赁、维修和进出口业务；二手设备及其他机器设备的收购、维修、租赁、销售；建筑装饰材料、新型路桥材料、石膏、水泥制品及类似制品、再生建筑材料及新材料的研发、生产、销售、技术推广及转让；建筑物拆除（不含爆破作业）；建筑设计；房屋建筑工程、市政公用工程、城市基础设施、土木工程、铁路、道路、隧道和桥梁工程施工总承包；建筑工业化装备、建筑预制件的研发、制造、销售；建筑大数据平台建设及服务；新能源装备研发、制造与销售，新能源的技术开发与服务、能源合同管理、售电服务；太阳能光伏电站系统集成及发电；风力发电机及其部件、增速机、电气机械及器材（含防爆型）、电机、变压器、电气传动系统及其相关设备、机电设备、主控、变桨、变流器控制柜及冰冷柜的生产和销售；石油钻采专业设备、智能装备、石油压裂成套设备、石油化工设备生产和销售；软件、技术研究开发及转让；技术、信息、认证咨询服务；房地产开发经营；物业管理；产业及园区开发、经营；企业管理服务；住宿、餐饮服务。
2.湖南同发投资有限公司（新增投资方，丙方2）
住所：长沙市天心区暮云街道万家丽南路二段989号
类型：有限责任公司(自然人投资或控股)
统一社会信用代码：914301037828876025
法定代表人：李鹏程
注册资本：19,800万人民币
经营范围：投资基础设施建设；城市基础设施建设；房地产开发经营；自营和代理各类商品及技术的进出口，但国家限定公司经营或禁止进出口的商品和技术除外；货物或技术进出口（国家禁止或涉及行政审批的货物和技术进出口除外）；出售、收购、利用国家保护野生动物或其产品；进出口商品检验鉴定；国家重点保护陆生野生动物驯养繁殖；国家重点保护水生野生动物驯养繁殖。
3.湖南省中欣房地产开发集团有限公司（新增投资方，丙方3）
住所：长沙市天心区刘家冲北路238号中欣国际26楼
类型：有限责任公司(自然人投资或控股)
统一社会信用代码：91430000712195926W
法定代表人：吴海涛
注册资本：10,000万人民币
经营范围：凭本企业资质证书从事房地产开发经营；计算机及信息产业技术应用及产品销售；经销百货、五金、交电、化工产品（不含危险及监控化学品）、纸张、机电设备、纺织品、建筑材料（不含硅酮胶）、普通机械、电脑及配件和法律、行政法规允许的矿产品、农副产品。
4.湖南安电工程技术服务合伙企业（有限合伙）（新增投资方，丙方4）
主要经营场所：长沙高新开发区桐梓坡西路408号麓谷林语小区I区综合体3栋5层5021号
类型：有限合伙企业
统一社会信用代码：91430100MA4PWBCU3Q
执行事务合伙人：周惠
经营范围：工程技术服务；高新技术服务；节能环保技术咨询服务；新材料及相关技术的研发、生产（限分支机构）、销售、运营；建筑节能产品的研发；建筑节能产品的制造（限分支机构）；建筑节能产品的销售；建筑节能产品的安装；应用软件开发；软件技术服务；信息技术咨询服务。
5.湖南安鑫物流有限公司（新增投资方，丙方5）
住所：长沙县星沙镇*路17号湘商世纪鑫城1幢2902号房
类型：有限责任公司(自然人投资或控股)
统一社会信用代码：91430121557613349R
法定代表人：刘艳萍
注册资本：20,000万人民币
经营范围：普通货物运输；国内货运代理；物流代理服务；仓储代理服务；打包、装卸、运输全套服务代理；建筑工程机械与设备租赁。
6.长沙澄海实业有限公司（新增投资方，丙方6）
住所：长沙市望城区月亮岛街道中华岭村桑梓片六组(润和紫郡对面)
类型：有限责任公司(自然人投资或控股)
统一社会信用代码：91430122734779789F
法定代表人：谭震
注册资本：8,000万人民币
经营范围：液化石油气、灶具及配件、机电产品的销售；家用电器、润滑油的批发；气瓶充装；普通货物运输；道路危险货物运输；物流代理服务。
7.湖南省八环建筑工程有限公司（新增投资方，丙方7）
住所：长沙市开福区东风路146号8楼
类型：有限责任公司(自然人投资或控股)
统一社会信用代码：9143000061680156XE
法定代表人：郭小群
注册资本：5,980万人民币
经营范围：房屋建筑工程施工总承包业务；房地产销售代理；广告制作与发布。
以上投资方与本公司不存在关联关系。
三、风险投资标的的基本情况
1.增资方式：
投资主体中，新增投资方及原股东增资扩股的增资方式、金额及比例为：
■
2.标的公司基本情况
（1）企业名称：长沙三银房地产开发有限公司（甲方）
（2）住所：湖南省长沙市岳麓区观沙岭街道滨江路53号楷林国际大厦D座102号
（3）类型：有限责任公司（自然人投资或控股的法人独资）
（4）统一社会信用代码：91430104MA4LN0EH7A
（5）法定代表人：唐修国
（6）注册资本：1,000万人民币
（7）经营范围：房地产开发经营；物业管理。
（8）增资前、后的股权结构：
■
（9）三银地产主要财务指标（最近一年又一期）：
单位：元
■
四、增资扩股协议的主要内容
（一）增资扩股金额、比例
■
（二）利润分配
协议各方同意，甲方应对股东借款及对外贷款制定还款计划，在偿还完年度计划的股东借款及甲方公司对外贷款，且公司在弥补完以前年度亏损并提取法定公积金，以及将经营所产生的税后利润留存至公司至少六个月的营运资金后，公司尚有资金可以进行利润分配的，公司方能向股东方分配利润。具体还款计划由甲方董事会决定。
（三）增资扩股后的法人治理结构
1.股东会
增资后，乙方与丙方平等成为甲方的股东，所有股东依照《中华人民共和国公司法》以及其他法律法规、部门规章和增资扩股后的新公司《章程》的规定按其股权比例享有权利、承担义务。
2.董事会
董事会由7名董事组成，其中乙方选派2名董事，丙方选派5名董事。未选派董事的股东可通过选派监事、公司*管理人员等方式参与公司治理，甲方在项目建设期间按季度向所有股东报送动态成本和财务报表。
3.监事会
增资后，公司监事会成员由公司股东推举，原则上由未选派董事人选的股东优先推举。
4.经营管理团队
（1）增资后，公司总经理及财务总监由乙方推荐并经董事会选举产生。
（2）乙方负责甲方的经营管理、财务决策和资本运作，由公司总经理选派乙方人员组成经营管理团队进行具体操作。
（3）总经理有权决定股东派驻项目代表的报酬事宜并计入公司经营管理费用。具体应以甲方签署的经营管理团队聘请合同为准。
（四）违约责任
任何一方违反本协议项下的义务、违反本协议项下所作出的任何陈述与保证、或陈述与保证被证明不真实、不准确或不完整，违约方均应当向守约方承担违约责任，并赔偿给守约方造成的直接及间接经济损失。
（五）生效条件及生效时间：本协议自各方签章之日起生效。
五、投资的目的、存在的风险和对公司的影响
（一）投资目的
在不影响公司正常经营及风险可控的前提下，合理使用闲置自有资金进行此次投资，充分利用公司资源，提高公司的资金使用效率，拓展业务，增加效益，促进公司健康、持续、快速发展，为公司与股东创造更大的收益。
（二）资金来源
资金来源为公司自有资金。
（三）可能产生的风险
由于所投资的企业主要从事房地产开发业务，存在开发风险、宏观调控政策及决策风险、市场销售风险。
1.开发风险
（1）房地产开发成本主要受原材料、设备、人工等要素价格的影响，如果要素价格上涨，则将导致三银地产开发成本增加。
（2）房地产项目开发过程中须获得的政府许可，涉及国土、房管、建设、规划、消防和环保等多个政府部门的审批，上述任何环节的不利变化，都可能导致三银地产面临项目开发周期延长、成本上升。
2.宏观调控政策及决策风险
国家对于土地、房地产市场等宏观调控及产业政策的变化，可能给三银地产项目开发带来不确定性。若三银地产不能适应宏观调控政策的变化做出合理的决策，则有可能对三银地产的经营管理、未来发展造成不利的影响。针对该风险，三银地产将重视可行性分析，充分搜集项目相关的各类信息，做好项目的市场分析、财务评估、项目的敏感因素评估等，确定房地产开发项目盈利的可能性，并在此基础上做出决策。
3.市场销售风险
若三银地产项目所在城市房地产市场楼价下降，成交量萎缩，销售压力将增加，对收益产生较大的影响，三银地产面临短期收益波动的风险。针对该风险，三银地产将密切关注市场动态，了解需求状况，采用灵活合理的营销方式，拓宽营销渠道，完善定价机制，避免或减轻销售和价格风险。
三银地产的预期收益受到行业所处的外部环境以及自身运营情况影响，存在一些不确定因素，请广大投资者注意风险。
（四）对公司的影响
公司以自有资金进行此次投资，是在确保公司日常运营和资金安全的前提下实施的，不会影响公司日常资金正常周转需要及公司主营业务的正常开展。可提高资金使用效率，提升公司效益。因此，此次投资对公司当前主业未来的发展不构成重大影响。
六、公告日前十二个月内进行风险投资的情况
本公告披露日前十二个月，公司未进行任何风险投资（不含本次投资）。
七、公司承诺
公司承诺进行风险投资实施后的十二个月内，不使用闲置募集资金暂时补充流动资金、将募集资金投向变更为*性补充流动资金、将超募资金*性用于补充流动资金或者归还银行贷款。
八、备查文件
1.公司第四届董事会第八次会议决议；
2.公司第四届监事会第六次会议决议；
3.2018年第一次临时股东大会决议；
4.《关于长沙三银房地产开发有限公司之增资扩股协议》。
特此公告！
湖南汉森制药股份有限公司董事会
2018年12月29日
今天的内容先分享到这里了，读完本文《汉森制药公司简介》之后，是否是您想找的答案呢？想要了解更多汉森制药公司简介、外盘期货在线喊单数据提前布局相关的财经新闻请继续关注本站，是给小编*的鼓励。
